Physician Wealth Advisors’s Design Therapeutics DSGN Stock Holding History

Physician Wealth Advisors’s Portfolio DSGN Stock Details DSGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.88K	Hold	268	–	–	﹤0.01%	1210
2026 Q1	$2.85K	Hold	268	–	–	﹤0.01%	1199
2025 Q4	$2.51K	Hold	268	–	–	﹤0.01%	1191
2025 Q3	$2.02K	Hold	268	–	–	﹤0.01%	1219
2025 Q2	$904	Buy	+268	New	+$1K	﹤0.01%	1496

Other funds holding DSGN

CUAMC

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return

Oppenheimer & Co New York $9.37B AUM 36.4% 1-Year Est. Return

AlphaCentric Advisors San Juan, Puerto Rico $118M AUM

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Physician Wealth Advisors's DSGN Position: Q2 2026 in Review

Physician Wealth Advisors held its Design Therapeutics (DSGN) position steady in Q2 2026 at 268 shares worth $3.88K. The position accounts for ﹤0.01% of the portfolio, ranked #1210.

Physician Wealth Advisors first reported a position in DSGN in Q2 2025 and has held it in 5 quarters since. 23 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

Physician Wealth Advisors held 268 shares of Design Therapeutics worth $3.88K as of Q2 2026.
Physician Wealth Advisors left its Design Therapeutics share count unchanged in Q2 2026.
Design Therapeutics made up ﹤0.01% of Physician Wealth Advisors's portfolio in Q2 2026, its #1210 holding.
Physician Wealth Advisors first reported a position in Design Therapeutics in Q2 2025 and has held it in 5 quarters since.
23 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on Physician Wealth Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.